Osimertinib‑induced erythromelalgia: A case report

Bolzon,Anna; Guidotti,Alessia; Alaibac,Mauro Alessandro Salvatore

doi:10.3892/etm.2024.12561

July-2024 Volume 28 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2024 Volume 28 Issue 1

Full Size Image

Case Report Open Access

Osimertinib‑induced erythromelalgia: A case report

Authors:
- Anna Bolzon
- Alessia Guidotti
- Mauro Alessandro Salvatore Alaibac
View Affiliations / Copyright

Affiliations: Dermatology Unit, Department of Medicine, University of Padova, I‑35121 Padova, Italy

Copyright: © Bolzon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 273
|
Published online on: May 2, 2024

https://doi.org/10.3892/etm.2024.12561
Expand metrics +

Abstract

The present study reports a case of osimertinib‑induced erythromelalgia in a patient with metastatic lung adenocarcinoma. Osimertinib is an antineoplastic drug that irreversibly inhibits the epidermal growth factor receptor (EGFR) pathway by binding to the intracellular receptor tyrosine kinase site, thus preventing EGFR signal transduction. A 77‑year‑old female with a lung adenocarcinoma recurrence with secondary metastases was prescribed osimertinib therapy. The patient presented with painful erythema and warmth in the distal phalanges of all fingers on both hands, which worsened with heat and relieved with cold. Based on clinical data, erythromelalgia was diagnosed. Considering the age of onset, a primary erythromelalgia was ruled out. Further investigations excluded other secondary causes of erythromelalgia, therefore osimertinib was suspected as the cause. Although no cases of EGFR inhibitor‑induced erythromelalgia have been reported, cutaneous adverse events induced by EGFR inhibitors have been documented. The present case may be the first evidence of osimertinib‑induced erythromelalgia and may help clinicians to properly support patients who develop this EGFR inhibitor adverse event.

View Figures

View References

1	Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM, Franchina T, Santarpia M, Silvestris N and Spina E: Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database. Front Oncol. 12(1005626)2022.PubMed/NCBI View Article : Google Scholar
2	Kozuki T: Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 46:291–298. 2016.PubMed/NCBI View Article : Google Scholar
3	Mann N, King T and Murphy R: Review of primary and secondary erythromelalgia. Clin Exp Dermatol. 44:477–482. 2019.PubMed/NCBI View Article : Google Scholar
4	Iskandar AS, Hwang A and Dasanu CA: EGFR inhibitor-induced cut-like skin lesions of the fingers. BMJ Case Rep. 2018(bcr2017224144)2018.PubMed/NCBI View Article : Google Scholar
5	Funai K: Rare ashy dermatosis-like hyperpigmentation associated with osimertinib. Thorac Cancer. 13:1436–1437. 2022.PubMed/NCBI View Article : Google Scholar
6	Iriarte C, Young JH, Rabin MS and LeBoeuf NR: Osimertinib-induced cutaneous vasculitis responsive to low-dose dapsone without interruption of anticancer therapy: A case report and review of the literature. JTO Clin Res Rep. 3(100415)2022.PubMed/NCBI View Article : Google Scholar
7	Rittberg R, Ho C and Wang Y: Acute onset of a life-threatening skin toxicity due to osimertinib: Severe psoriasis versus toxic epidermal necrolysis. Cureus. 14(e24513)2022.PubMed/NCBI View Article : Google Scholar
8	Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, et al: Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 35:1288–1296. 2017.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Osimertinib‑induced erythromelalgia: A case report

This article is mentioned in:

Abstract

Figure 1

Related Articles